Disclaimer: This is a simplified summary of a public company filing. See full disclaimer here.

FutureTech II Acquisition Corp.

CIK: 18894502 Annual ReportsLatest: 2025-04-09

10-K / April 9, 2025

Revenue:N/A
Income:-$746,953

10-K / April 5, 2024

Revenue:N/A
Income:$2,911,502

10-K / April 9, 2025

Company Summary

Business Overview

  • Company Name: FutureTech II Acquisition Corp.
  • Type: Blank check company (Special Purpose Acquisition Company - SPAC)
  • Formation Date: August 19, 2021
  • Purpose: To effect a merger, asset acquisition, stock purchase, reorganization, or similar business combination with one or more target businesses.
  • Industry Focus:
    • Disruptive technology sectors, specifically:
      • Artificial Intelligence (AI)
      • Robotics
      • Biomedical life sciences
    • Target geographic region: U.S.
    • Not pursuing initial business combinations with entities primarily in China (including Hong Kong and Macau)
  • Target Characteristics:
    • Companies with positive cash flow or compelling technology with a clear path to profitability.
    • Companies with large market potential, especially in hardware tech, biomedical sciences, AI, and Robotics.
    • Businesses with proprietary or patented technology, significant market position, or distinct competitive advantages.
    • Companies at inflection points that could benefit from operational improvements.

Management and Strategy

  • Management Lead: Ray Chen, CEO and Chairman
    • Experience in tech, media, and investment sectors, including prior roles as CFO and COO of other SPACs.
  • Key Strategy:
    • Source, acquire, and manage technology-focused businesses.
    • Drive operational improvements and growth organically or through acquisitions.
    • Leverage relationships with deal sources to maintain a strong pipeline of potential targets.
    • Use a criteria-based evaluation process, with flexibility to pursue targets outside initial guidelines.

Financials and Operations

  • Initial Public Offering (IPO):
    • Date: February 18, 2022
    • Units offered: 11,500,000 units at $10.00 each
    • Gross proceeds: $115,000,000
  • Private Placement:
    • 520,075 units purchased by the Sponsor at $10.00 each
    • Total gross proceeds: $5,200,750
  • Trust Fund:
    • Approximately $117.3 million (from IPO and private placement) deposited in trust for public shareholders' benefit.
  • Offices: Located at 128 Gail Drive, New Rochelle, NY
  • Employees:
    • Currently, only one officer, who devotes varying amounts of time to the company's affairs.
  • Revenue and Income:
    • The company has not engaged in any business operations or generated revenue or income. Its purpose is to identify and complete a business combination.

Business Development

  • Current Status:
    • Engaged in searching for a target; no business operations or revenue yet.
    • Filed a Form S-4 regarding a merger with Longevity Biomedical, Inc., expected to be completed, subject to approvals.
  • Upcoming Milestones:
    • Deadline to complete business combination: August 18, 2025 (extensions possible).
    • Pending a potential business combination with Longevity Biomedical that would involve a merger and a name change.

Additional Notes

  • The company has not disclosed any number of customers, specific revenue, or profit since it is still in the pre-operation phase, solely focused on identifying and completing a merger with a target entity.
  • The company’s strategy includes targeting innovative tech firms with high growth potential in AI, robotics, and biomedical sciences within the U.S. market.